PMID- 20434199
OWN - NLM
STAT- MEDLINE
DCOM- 20100824
LR  - 20151119
IS  - 1097-6825 (Electronic)
IS  - 0091-6749 (Linking)
VI  - 125
IP  - 6
DP  - 2010 Jun
TI  - Mometasone furoate nasal spray reduces the ocular symptoms of seasonal allergic 
      rhinitis.
PG  - 1247-1253.e5
LID - 10.1016/j.jaci.2010.03.004 [doi]
AB  - BACKGROUND: Mometasone furoate nasal spray (MFNS), a potent intranasal 
      corticosteroid with proved efficacy in relieving nasal allergic rhinitis 
      symptoms, has demonstrated effectiveness in improving ocular symptoms associated 
      with seasonal allergic rhinitis (SAR) in retrospective analyses. OBJECTIVE: We 
      sought to evaluate prospectively the efficacy of MFNS in reducing total ocular 
      symptom scores (TOSSs) and individual ocular symptoms in subjects with SAR. 
      METHODS: Subjects 12 years or older (n = 429) with moderate-to-severe baseline 
      symptoms were randomized to MFNS, 200 microg once daily, or placebo in this 
      15-day, double-blind, parallel-group study. Subjects evaluated morning 
      instantaneous TOSSs and daily reflective TOSSs, total nasal symptom scores 
      (TNSSs; both instantaneous TNSSs and reflective TNSSs, respectively), and 
      individual ocular and nasal symptoms. Mean changes from baseline averaged over 
      days 2 to 15 (instantaneous) and days 1 to 15 (reflective) were calculated. 
      Quality of life was assessed by using the Rhinoconjunctivitis Quality of Life 
      Questionnaire. RESULTS: MFNS treatment yielded significant reductions from 
      baseline versus placebo in instantaneous TOSSs (-0.34, P = .026, coprimary end 
      point), instantaneous TNSSs (-0.88, P < .001, coprimary end point), reflective 
      TOSSs (-0.44, P = .005), and reflective TNSSs (-1.06, P < .001). Significant 
      decreases in all individual reflective ocular symptoms and instantaneous eye 
      itching/burning and eye watering/tearing were observed for MFNS versus placebo (P 
      < .05). Numeric improvements in instantaneous eye redness were seen but did not 
      reach statistical significance. Improvements in Rhinoconjunctivitis Quality of 
      Life Questionnaire total scores and individual symptom domains were achieved with 
      MFNS treatment versus placebo (P < .001). MFNS was well tolerated. CONCLUSION: 
      This prospective study demonstrates that MFNS significantly reduces ocular 
      symptoms in subjects with SAR.
CI  - Copyright (c) 2010 American Academy of Allergy, Asthma & Immunology. Published by 
      Mosby, Inc. All rights reserved.
FAU - Prenner, Bruce M
AU  - Prenner BM
AD  - Allergy Associates Medical Group, San Diego, Calif., USA. prenner@aaamg.com
FAU - Lanier, Bobby Q
AU  - Lanier BQ
FAU - Bernstein, David I
AU  - Bernstein DI
FAU - Shekar, Tulin
AU  - Shekar T
FAU - Teper, Ariel
AU  - Teper A
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Allergy Clin Immunol
JT  - The Journal of allergy and clinical immunology
JID - 1275002
RN  - 0 (Aerosols)
RN  - 0 (Anti-Allergic Agents)
RN  - 0 (Pregnadienediols)
RN  - 04201GDN4R (Mometasone Furoate)
SB  - IM
CIN - J Allergy Clin Immunol. 2011 Jan;127(1):288-9; author reply 289. PMID: 21047674
MH  - Administration, Intranasal
MH  - Adult
MH  - Aerosols/*administration & dosage/adverse effects
MH  - Anti-Allergic Agents/*administration & dosage/adverse effects
MH  - Double-Blind Method
MH  - Female
MH  - Headache/etiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mometasone Furoate
MH  - Nasal Obstruction/drug therapy
MH  - Pregnadienediols/*administration & dosage/adverse effects
MH  - Pruritus/drug therapy
MH  - Quality of Life
MH  - Retrospective Studies
MH  - Rhinitis, Allergic, Seasonal/*drug therapy/physiopathology
MH  - Tears
EDAT- 2010/05/04 06:00
MHDA- 2010/08/25 06:00
CRDT- 2010/05/04 06:00
PHST- 2009/04/24 00:00 [received]
PHST- 2010/03/04 00:00 [revised]
PHST- 2010/03/04 00:00 [accepted]
PHST- 2010/05/04 06:00 [entrez]
PHST- 2010/05/04 06:00 [pubmed]
PHST- 2010/08/25 06:00 [medline]
AID - S0091-6749(10)00425-2 [pii]
AID - 10.1016/j.jaci.2010.03.004 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol. 2010 Jun;125(6):1247-1253.e5. doi: 
      10.1016/j.jaci.2010.03.004.